Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
OBSERVATIONAL
2020-09-01
2021-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Immunity to coronavirus 2019 (COVID-19) infection can be determined by detecting the presence of antibodies to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Immunoglobulins (Ig) to the SARS-CoV-2 develop during the second and third week of COVID-19 disease and can be detected by analyses conducted using laboratory tests. Accurate and scalable point-of-care testing (POCT) for the diagnosis of COVID-19 immunity would allow community diagnostic to be upscaled enormously. POCT for COVID-19 antibodies is possible using small disposable kits. POCT immunity testing using disposable kits will be imperative for effective surveillance and vaccinations programmes.
The study aims to test a novel, rapid antibody testing kit (IgG and IgM) in order to confirm its accuracy in a healthy volunteer population. The antibody testing kit intended for use in the study has already been CE marked for this purpose.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
200 healthy volunteers will be enrolled into one of two cohorts:100 who have been confirmed to have had COVID-19 in the past (either by previous positive PCR swab or positive antibody test) and 100 thought not to have been affected by COVID-19. Once they have provided written informed consent to participate, volunteers will be invited to attend a 30 minutes appointment for testing. Prior to testing they will be asked to complete a short questionnaire to collect demographic information and details about previous symptoms of COVID-19.
A finger prick blood sample will be taken from the patient and then tested in the ARIA antibody kit. Afterwards, a routine blood sample (10 ml) will then be taken from the participant. The blood sample will be used in three separate ways:
1. A small sample of blood will be immediately removed from the sample bottle and placed into an ARIA antibody test kit.
2. One blood tube will be immediately centrifuged and a sample of plasma removed for use in the ARIA antibody testing kit.
3. One tube will be sent to the designated laboratory for formal COVID-19 ELISA antibody testing.
The ARIA antibody kit will be used to identify the presence of COVID-19 antibodies. The results will be compared to a laboratory enzyme-linked immunosorbent assay (ELISA) for COVID-19 antibodies. Once samples have arrived at the designated study laboratory they will undergo a specified ELSIA test for COVID-19 antibodies conducted according to the laboratory standard operating procedure for that test. For each sample type analysed (finger prick blood, venous blood, and plasma) the sensitivity and specificity of the test will be calculated against the results of the laboratory ELISA test.
Afterwards a brief exit questionnaire will be completed by the participant to document their experience of the study.
Recruitment is expected to be completed within six months of commencing the study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Previously COVID-19 positive
Previously confirmed PCR positive for COVID-19 And/or positive COVID-19 antibody test in the past six months
COVID-19 antibody point of care test kit
A disponible point of care test that identifies the presence of antibodies to COVID-19
Previously COVID19 negative
No previous symptoms of COVID-19
COVID-19 antibody point of care test kit
A disponible point of care test that identifies the presence of antibodies to COVID-19
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
COVID-19 antibody point of care test kit
A disponible point of care test that identifies the presence of antibodies to COVID-19
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* For the positive group: PCR confirmed COVID-19 infection and/or positive antibodies test in the past six months,
* For the negative group: Never had symptoms of COVID-19
* Able to attend hospital for a blood and finger-prick test
Exclusion Criteria
* Positive COVID-19 test result in the last 14 days
* Receiving or have received immunosuppression (including systemic corticosteroids) in the last 12 months
* Children (aged \< 18years)
* Pregnancy
* Prisoners
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Royal Free Hospital NHS Foundation Trust
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Daniel Martin, MB ChB
Role: PRINCIPAL_INVESTIGATOR
Royal Free Hospital NHS Foundation Trust
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
134035
Identifier Type: -
Identifier Source: org_study_id